Sequential Therapy of Acute Kidney Injury with a DNA Nanodevice.
Nano Lett
; 21(10): 4394-4402, 2021 05 26.
Article
in English
| MEDLINE | ID: covidwho-1230861
ABSTRACT
The high demand for acute kidney injury (AKI) therapy calls the development of multifunctional nanomedicine for renal management with programmable pharmacokinetics. Here, we developed a renal-accumulating DNA nanodevice with exclusive kidney retention for longitudinal protection of AKI in different stages in a renal ischemia-reperfusion (I/R) model. Due to the prolonged kidney retention time (>12 h), the ROS-sensitive nucleic acids of the nanodevice could effectively alleviate oxidative stress by scavenging ROS in stage I, and then the anticomplement component 5a (aC5a) aptamer loaded nanodevice could sequentially suppress the inflammatory responses by blocking C5a in stage II, which is directly related to the cytokine storm. This sequential therapy provides durable and pathogenic treatment of kidney dysfunction based on successive pathophysiological events induced by I/R, which holds great promise for renal management and the suppression of the cytokine storm in more broad settings including COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Reperfusion Injury
/
Acute Kidney Injury
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Nano Lett
Year:
2021
Document Type:
Article
Affiliation country:
Acs.nanolett.1c01044
Similar
MEDLINE
...
LILACS
LIS